Scholarlink

Background <p>Vital pulpotomy is routinely performed to maintain radicular pulp vitality in carious primary molars, yet the long‑standing use of formocresol persists despite concerns about potential cytotoxic, mutagenic, and systemic effects. Chitosan, a naturally derived polysaccharide with antibacterial, hemostatic, and regenerative properties, has been proposed as a more biocompatible pulpotomy medicament.</p> Objective <p>To evaluate the radiographic and clinical results of conventional and chitosan-based pulpotomy medicaments (formocresol, ferric sulfate) in primary molars, based exclusively on randomized controlled trials.</p> Methods <p>From database inception to January 15, 2026, a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials was carried out in PubMed, Web of Science, Scopus, and the Cochrane Library. Cochrane RoB 2 was used to evaluate the risk of bias, and GRADE was used to score the certainty of the evidence. Mantel-Haenszel random-effect model was used to aggregate six-month clinical and radiographic success as risk ratios (RR) with 95% confidence intervals (CI).</p> Results <p>Four parallel‑group trials from India, involving 196 primary molars in children aged 4–9 years, met the inclusion criteria. Six‑month clinical success was identical for chitosan and conventional agents (83/86, 96.5% vs. 83/86, 96.5%; RR 1.00, 95% CI 0.94–1.06; I² = 0%), and radiographic success was likewise comparable (76/85, 89.4% vs. 73/85, 85.9%; RR 1.04, 95% CI 0.93–1.16; I² = 0%).</p> Conclusions <p>Chitosan‑based pulpotomy medicaments provide short‑term clinical and radiographic success rates comparable to formocresol and ferric sulfate and represent a biologically favorable alternative for pulpotomy in primary molars. Multicenter RCTs with 12–24‑month follow‑up and contemporary comparators are needed to clarify chitosan’s role in pediatric pulp therapy guidelines.</p> Trial registration <p>The study protocol was registered in the PROSPERO database (registration number CRD420251151362) on September 19, 2025.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chitosan pulpotomy medicaments versus conventional agents in primary teeth: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月6日

查看全文
  • Prachi Kumari,
  • Kanika Singh Dhull,
  • Brahmananda Dutta,
  • Anandamoy Bagchi,
  • Vijayta Sharva,
  • Indira Mysore Devraj

摘要

Background

Vital pulpotomy is routinely performed to maintain radicular pulp vitality in carious primary molars, yet the long‑standing use of formocresol persists despite concerns about potential cytotoxic, mutagenic, and systemic effects. Chitosan, a naturally derived polysaccharide with antibacterial, hemostatic, and regenerative properties, has been proposed as a more biocompatible pulpotomy medicament.

Objective

To evaluate the radiographic and clinical results of conventional and chitosan-based pulpotomy medicaments (formocresol, ferric sulfate) in primary molars, based exclusively on randomized controlled trials.

Methods

From database inception to January 15, 2026, a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials was carried out in PubMed, Web of Science, Scopus, and the Cochrane Library. Cochrane RoB 2 was used to evaluate the risk of bias, and GRADE was used to score the certainty of the evidence. Mantel-Haenszel random-effect model was used to aggregate six-month clinical and radiographic success as risk ratios (RR) with 95% confidence intervals (CI).

Results

Four parallel‑group trials from India, involving 196 primary molars in children aged 4–9 years, met the inclusion criteria. Six‑month clinical success was identical for chitosan and conventional agents (83/86, 96.5% vs. 83/86, 96.5%; RR 1.00, 95% CI 0.94–1.06; I² = 0%), and radiographic success was likewise comparable (76/85, 89.4% vs. 73/85, 85.9%; RR 1.04, 95% CI 0.93–1.16; I² = 0%).

Conclusions

Chitosan‑based pulpotomy medicaments provide short‑term clinical and radiographic success rates comparable to formocresol and ferric sulfate and represent a biologically favorable alternative for pulpotomy in primary molars. Multicenter RCTs with 12–24‑month follow‑up and contemporary comparators are needed to clarify chitosan’s role in pediatric pulp therapy guidelines.

Trial registration

The study protocol was registered in the PROSPERO database (registration number CRD420251151362) on September 19, 2025.